Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Limitations of current therapies
22 evidence topics · 24 sources
Summary: HLA restriction of tebentafusp and absence of approved therapy for HLA-A∗02:01-negative disease
Tebentafusp, the only FDA-approved systemic therapy for metastatic uveal melanoma, is approved by the FDA and the EMA as first-line systemic treatment for HLA-A∗02:01-positive patients, and only approximately 45% of individuals in the United States and Europe are HLA-A∗02:01-positive. HLA-A∗02:01-negative patients “continue to lack an established standard of care” and comprised 49% of individuals prescreened in the tebentafusp trial. There is no consensus on first-line systemic therapy for HLA-A∗02:01-negative patients; their current options are immune checkpoint inhibitors, “which are not specifically approved for mUM”, and participation in clinical trials, and the National Cancer Institute states that no effective method of systemic treatment has been identified for metastatic ocular melanoma. Within its eligible population, tebentafusp produced a 5-year overall survival rate of 16% versus 8% in the control group with an 11% overall response rate, almost all treated patients eventually progressed, and Piperno-Neumann et al. state that “a high unmet need remains”. Tebentafusp requires weekly intravenous administration with observation periods at initiation and inpatient monitoring for the first 3 to 4 infusions because of the risk of cytokine release syndrome, which occurred in 89% of tebentafusp-treated patients.
Summary: response, survival, and toxicity with immune checkpoint inhibitors
With PD-1 inhibitors in uveal melanoma, the objective response rate is below 5%, median progression-free survival 3 months, and 1-year overall survival approximately 50%. A meta-analysis reported a pooled objective response rate of 9.2% (4.1% for anti-CTLA4, 7.1% for anti-PD(L)1, and 13.5% for anti-CTLA4 plus anti-PD1) and a median overall survival of 11.5 months; a second meta-analysis of 1414 patients reported response rates of 3.4% with single-agent and 12.4% with dual checkpoint inhibition and median overall survival of 9.8 and 16.3 months. In two phase 2 trials of nivolumab plus ipilimumab, objective response rates were 11% and 18% and median overall survival 12 and 19 months. Pham et al. conclude that checkpoint inhibitors have limited efficacy in metastatic uveal melanoma. Dual checkpoint inhibition adds toxicity: in the 64 participants with metastatic uveal melanoma in CheckMate 401, 64% had grade 3-4 treatment-related adverse events and 30% discontinued; grade 3-4 treatment-related adverse events occurred in 40% of patients in one phase 2 trial and severe treatment-related adverse events in 39.1% of patients in a German series; 34 of 89 patients in a retrospective study across 14 academic medical centers discontinued for toxicity; and treatment-related discontinuation was 23% with nivolumab plus ipilimumab versus 2%-5% with pembrolizumab, without a clear survival advantage for the combination.
Summary: scope and risks of liver-directed therapy
Liver-directed therapy treats liver metastases alone: percutaneous hepatic perfusion “does not address extrahepatic disease”. Most patients have multifocal and small liver metastases, and around 10% are eligible for local therapy, with perioperative mortality and morbidity after surgery of approximately 2% and 14%. The FOCUS study of melphalan percutaneous hepatic perfusion enrolled patients with liver tumor involvement of up to 50% and excluded those with moderate or severe cirrhosis, portal hypertension, or NYHA II-IV status; grade 3 and 4 treatment-emergent adverse events occurred in 81.1% of patients, including thrombocytopenia in 54.7%, and 17.9% discontinued treatment because of them. In an earlier randomized trial, four deaths were attributed to melphalan percutaneous hepatic perfusion, and median overall survival did not differ significantly between arms (10.6 versus 10.0 months). Isolated hepatic perfusion is non-repeatable and carries higher morbidity and mortality, and in the SCANDIUM trial the primary endpoint was not met (24-month overall survival 46.5% versus 29.5%, P=0.12). Adding ipilimumab plus nivolumab to percutaneous hepatic perfusion raised grade 3-4 treatment-related adverse events from 41% to 82%.
Summary: outcomes with chemotherapy and earlier targeted therapies
Response rates to chemotherapy are below 10% regardless of the cytotoxic agent, with no demonstrated overall survival benefit over best supportive care. Across 40 studies, complete or partial remissions occurred in 39 of 841 patients (4.6%), with no responses in 22 of the 40 studies. In randomized trials, no objective responses were observed with temozolomide or dacarbazine and median overall survival was 9.1 months, the objective response rate with placebo plus dacarbazine was 0%, and median overall survival with temozolomide or dacarbazine was 7.3 months in another trial. In a literature review, systemic treatment was associated with response rates below 10%, median progression-free survival of 1.8-7.2 months, and median overall survival of 5.2-19.0 months, and pooled survival fell from 52% at 1 year to 25% at 2 years and 13% at 3 years. Among earlier targeted agents, selumetinib plus dacarbazine did not significantly improve progression-free survival over placebo plus dacarbazine, the response rate to MEK inhibitors averaged 2.5% (range 0 to 14%), and 3% of 153 participants achieved a partial response with the protein kinase C inhibitor AEB071. A standard of care has not been defined despite numerous phase 2 studies.
Response and survival with systemic treatment: guideline summary of a literature review
“According to findings from a literature review, systemic treatment of metastatic UM was associated with low response rates (<10%), low median PFS (1.8-7.2 months) and OS (5.2-19.0 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Few prospective studies have been published on this rare cancer, especially randomised controlled trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
No consensus on first-line systemic therapy for HLA-A∗02:01-negative disease
Unmet need and treatment options for HLA-A∗02:01-negative patients after the five-year tebentafusp analysis
Proportion of patients eligible for tebentafusp by HLA-A∗02:01 status
Decline in pooled overall survival from 1 to 3 years across treatment modalities
“The median OS was 1.07 years (95% CI: 1.00–1.13), but the survival rate decreased rapidly from 52% (95% CI: 50–54) at 1 year to 25% (95% CI: 23–26) at 2 years, and 13% (95% CI: 12–15) at 3 years (Table 1 ).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limited efficacy of immune checkpoint inhibitors in meta-analysis
Pooled response and survival with immune checkpoint inhibitors in 1414 participants
“A random-effect model meta-analysis with generic inverse-variance was conducted, and 36 articles representing 41 cohorts of 1414 patients with metastatic uveal melanoma were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared to single-agent ICI, dual ICI led to better ORR (single-agent: 3.4% [95% CI 1.8–5.1]; dual-agent: 12.4% [95% CI 8.0–16.9]; P < 0.001), DCR (single-agent: 29.3%, [95% CI 23.4–35.2]; dual-agent: 44.3% [95% CI 31.7–56.8]; P = 0.03), and OS (single-agent: 9.8 months [95% CI 8.0–12.2]; dual-agent: 16.3 months [95% CI 13.5–19.7]; P < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Toxicity of nivolumab plus ipilimumab in the uveal melanoma subgroup of CheckMate 401: guideline summary
“In the subgroup of 64 patients with metastatic UM from CheckMate 401, ORR was 9% and median OS was 15 months; nivolumab–ipilimumab was associated with 64% grade 3-4 TRAEs, leading to discontinuation in 30% of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Grade 3 to 4 treatment-related adverse events with nivolumab plus ipilimumab
Treatment discontinuation for toxicity with nivolumab plus ipilimumab
“Overall, 82 (92%) of patients discontinued treatment, 34 due to toxicity and 27 due to progressive disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dual checkpoint inhibition yielded higher response rates than previous reports of single-agent immunotherapy in patients with mUM, but the efficacy is lower than in metastatic CM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Severe treatment-related adverse events with combined checkpoint blockade
Liver-confined scope of percutaneous hepatic perfusion
Procedural risks of hepatic perfusion: guideline statements
“The expected benefit should be weighed against the risk of AEs (haematological complications mostly), but serious cardiovascular and thromboembolic complications may occasionally occur.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The efficacy of IHP is similar to PHP, but IHP is non-repeatable and is associated with higher morbidity and mortality rates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Grade 3 to 4 adverse events and discontinuation with melphalan percutaneous hepatic perfusion, and morbidity of isolated hepatic perfusion
“Grades 3 and 4 TEAEs were reported in 81.1 % of the patients including grade 3 or 4 thrombocytopenia (54.7 %), leukopenia (33.7 %), anemia (32.6 %), and neutropenia (29.5 %) (Table 3 ).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment was discontinued for 17.9 % of the patients due to TEAEs (Table 3 ).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although IHP treats the whole liver and has shown promising tumor response rates, its use is restricted by a high risk of morbidity and mortality due to its invasive nature.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Deaths attributed to melphalan percutaneous hepatic perfusion
Overall survival primary endpoint not met with isolated hepatic perfusion
Eligibility for and morbidity of local treatment of liver metastases
“Most patients with UMLMs have multifocal and small metastases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Around 10% of the patients are eligible for local therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Perioperative mortality and morbidity rates after surgery of UMLMs are ∼2% and ∼14%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote